CNTB Long Call Strategy
CNTB (Connect Biopharma Holdings Limited), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB (Connect Biopharma Holdings Limited) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $138.5M, a beta of -0.20 versus the broader market, a 52-week range of 0.7-3.82, average daily share volume of 258K, a public-listing history dating back to 2021, approximately 62 full-time employees. These structural characteristics shape how CNTB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.20 indicates CNTB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on CNTB?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current CNTB snapshot
As of May 15, 2026, spot at $2.39, ATM IV 108.50%, IV rank 19.55%, expected move 31.11%. The long call on CNTB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on CNTB specifically: CNTB IV at 108.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a CNTB long call, with a market-implied 1-standard-deviation move of approximately 31.11% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CNTB expiries trade a higher absolute premium for lower per-day decay. Position sizing on CNTB should anchor to the underlying notional of $2.39 per share and to the trader's directional view on CNTB stock.
CNTB long call setup
The CNTB long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CNTB near $2.39, the first option leg uses a $2.39 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CNTB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CNTB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.39 | N/A |
CNTB long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CNTB long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CNTB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on CNTB
Long calls on CNTB express a bullish thesis with defined risk; traders use them ahead of CNTB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CNTB thesis for this long call
The market-implied 1-standard-deviation range for CNTB extends from approximately $1.65 on the downside to $3.13 on the upside. A CNTB long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CNTB IV rank near 19.55% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CNTB at 108.50%. As a Healthcare name, CNTB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CNTB-specific events.
CNTB long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CNTB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CNTB alongside the broader basket even when CNTB-specific fundamentals are unchanged. Long-premium structures like a long call on CNTB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CNTB chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CNTB?
- A long call on CNTB is the long call strategy applied to CNTB (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CNTB stock trading near $2.39, the strikes shown on this page are snapped to the nearest listed CNTB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CNTB long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CNTB long call priced from the end-of-day chain at a 30-day expiry (ATM IV 108.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CNTB long call?
- The breakeven for the CNTB long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CNTB market-implied 1-standard-deviation expected move is approximately 31.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CNTB?
- Long calls on CNTB express a bullish thesis with defined risk; traders use them ahead of CNTB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CNTB implied volatility affect this long call?
- CNTB ATM IV is at 108.50% with IV rank near 19.55%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.